These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 28700545)
41. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy? van Koningsbruggen-Rietschel S; Naehrlich L Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480 [No Abstract] [Full Text] [Related]
42. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242 [No Abstract] [Full Text] [Related]
43. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry. Elborn JS; Ramsey B; Wainwright C; Boyle M Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855 [No Abstract] [Full Text] [Related]
44. Understanding the relationship between sweat chloride and lung function in cystic fibrosis. Heltshe SL; Mayer-Hamblett N; Rowe SM Chest; 2013 Oct; 144(4):1418. PubMed ID: 24081360 [No Abstract] [Full Text] [Related]
45. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
47. Lung clearance index response in patients with CF with class III CFTR mutations. Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510 [No Abstract] [Full Text] [Related]
48. Ivacaftor for patients with cystic fibrosis. Wainwright CE Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205 [TBL] [Abstract][Full Text] [Related]
51. Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy. Hayes D; Warren PS; McCoy KS; Sheikh SI J Pediatr Gastroenterol Nutr; 2015 May; 60(5):578-9. PubMed ID: 25688481 [TBL] [Abstract][Full Text] [Related]
52. Improvement of sinus disease in cystic fibrosis with ivacaftor therapy. Hayes D; McCoy KS; Sheikh SI Am J Respir Crit Care Med; 2014 Aug; 190(4):468. PubMed ID: 25127305 [No Abstract] [Full Text] [Related]
53. Aquagenic wrinkling of the palms in a patient with cystic fibrosis. Grasemann H; Ratjen F; Solomon M N Engl J Med; 2013 Dec; 369(24):2362-3. PubMed ID: 24328486 [No Abstract] [Full Text] [Related]
54. PharmGKB summary: very important pharmacogene information for CFTR. McDonagh EM; Clancy JP; Altman RB; Klein TE Pharmacogenet Genomics; 2015 Mar; 25(3):149-56. PubMed ID: 25514096 [No Abstract] [Full Text] [Related]
55. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis. Ramsey BW; Welsh MJ Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323 [No Abstract] [Full Text] [Related]
56. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant. Mitchell RM; Jones AM; Barry PJ Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080 [TBL] [Abstract][Full Text] [Related]